



Update Summary

Entity name

WELLNEX LIFE LIMITED

Announcement Type

Update to previous announcement

Date of this announcement

28/2/2025

Reason for update to a previous announcement

Update on timetable (issue date).

Refer to next page for full details of the announcement

Part 1 - Entity and announcement details

1.1 Name of +Entity

WELLNEX LIFE LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

1.2 Registered Number Type

ABN

Registration Number

77150759363

1.3 ASX issuer code

WNX

1.4 The announcement is

Update/amendment to previous announcement

1.4a Reason for update to a previous announcement

Update on timetable (issue date).

1.4b Date of previous announcement to this update

10/2/2025

1.5 Date of this announcement

28/2/2025

1.6 The Proposed issue is:

A standard +pro rata issue (non-renounceable or renounceable)

1.6a The proposed standard +pro rata issue is:

+ Non-renounceable



Part 3 - Details of proposed entitlement offer issue

Part 3A - Conditions

3A.1 Do any external approvals need to be obtained or other conditions satisfied before the entitlement offer can proceed on an unconditional basis?

No

Part 3B - Offer details

+Class or classes of +securities that will participate in the proposed issue and +class or classes of +securities proposed to be issued

ASX +security code and description

WNX : ORDINARY FULLY PAID

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?

Existing class

Will the proposed issue of this +security include an offer of attaching +securities?

No

If the entity has quoted company options, do the terms entitle option holders to participate on exercise?

No

Details of +securities proposed to be issued

ASX +security code and description

WNX : ORDINARY FULLY PAID

ISIN Code (if Issuer is a foreign company and +securities do not have +CDIs issued over them)

ISIN Code for the entitlement or right to participate in a non-renounceable issue (if Issuer is foreign company and +securities do not have +CDIs issued over them)

Offer ratio (ratio to existing holdings at which the proposed +securities will be issued)

The quantity of additional +securities to be issued

1

For a given quantity of +securities held

1

What will be done with fractional entitlements?

Maximum number of +securities proposed to be issued (subject to

**rounding)**

Fractions rounded up to the next whole number 34,099,861

Offer price details for retail security holders

In what currency will the offer be made?	What is the offer price per +security for the retail offer?
AUD - Australian Dollar	AUD 0.65000

Oversubscription & Scale back details

Will individual +security holders be permitted to apply for more than their entitlement (i.e. to over-subscribe)?
Yes

Describe the limits on over-subscription

Eligible Shareholders are also entitled to subscribe for any New Shares not subscribed for by other Eligible Shareholders in accordance with the Offer (Shortfall Offer). For more details, please refer to the prospectus released to ASX on 10 February 2025.

Will a scale back be applied if the offer is over-subscribed?
Yes

Describe the scale back arrangements

(a) if the number of Shortfall Shares available for subscription is less than the aggregate number of Shortfall Shares applied for by all unsatisfied Applicants, the number of Shortfall Shares applied for, scaled on a pro rata basis according to all unsatisfied Applicants' respective shareholdings in Wellnex as at the Closing Date for the Offer. For more details, please refer to the prospectus released to ASX on 10 February 2025.

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?
Yes

Part 3C - Timetable

3C.1 +Record date

13/2/2025

3C.2 Ex date

12/2/2025

3C.4 Record date

13/2/2025

3C.5 Date on which offer documents will be sent to +security holders entitled to participate in the +pro rata issue

17/2/2025



3C.6 Offer closing date

26/2/2025

3C.7 Last day to extend the offer closing date

21/2/2025

3C.9 Trading in new +securities commences on a deferred settlement basis

27/2/2025

3C.11 +Issue date and last day for entity to announce results of +pro rata issue

4/3/2025

3C.12 Date trading starts on a normal T+2 basis

5/3/2025

3C.13 First settlement date of trades conducted on a +deferred settlement basis and on a normal T+2 basis

7/3/2025

Part 3E - Fees and expenses

3E.1 Will there be a lead manager or broker to the proposed offer?

Yes

3E.1a Who is the lead manager/broker?

Reach Markets Pty Ltd (Reach).

3E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?

1% of total capital raising fees.

5.5% of any shareholders taking up the Rights Issue and the total dollar amount raised in the Shortfall Placement by Reach.

3E.2 Is the proposed offer to be underwritten?

No

3E.3 Will brokers who lodge acceptances or renunciations on behalf of eligible +security holders be paid a handling fee or commission?

No

3E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed offer

Part 3F - Further Information

3F.1 The purpose(s) for which the entity intends to use the cash raised by the proposed issue

Redeeming the convertible notes in full; paying the outstanding deferred consideration owed to the vendors of the Pain Away business; and general working capital purposes, including but not limited to the costs of the Offer and the proposed AIM listing.

3F.2 Will holdings on different registers or subregisters be aggregated for the purposes of determining



entitlements to the issue?

No

3F.3 Will the entity be changing its dividend/distribution policy if the proposed issue is successful?

No

3F.4 Countries in which the entity has +security holders who will not be eligible to participate in the proposed issue

3F.5 Will the offer be made to eligible beneficiaries on whose behalf eligible nominees or custodians hold existing +securities

No

3F.6 URL on the entity's website where investors can download information about the proposed issue

3F.7 Any other information the entity wishes to provide about the proposed issue

3F.8 Will the offer of rights under the rights issue be made under a +disclosure document or product disclosure statement under Chapter 6D or Part 7.9 of the Corporations Act (as applicable)?

No

3F.9 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:

The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)